LifeSpan Vision Ventures today announced that it has closed an investment in Remedium Bio.

Remedium is a biotechnology company focused on the development of treatments for large unmet clinical needs. To enable this, we developed a revolutionary gene therapy platform, which enables safe, effective, and durable delivery of therapeutic genes while allowing for simple post-treatment dose adjustment. The Prometheus™ adjustable gene therapy platform enables replacement of a broad range of subcutaneously administered protein treatments with a single injection, adjustable dose gene therapy. The system has an exceptionally high degree of specificity and remains localized to the site of the subcutaneous injection, offering a safe and durable, single injection alternative, at a fraction of the current protein-based therapeutic treatment cost. Remedium's pipeline includes several disease modifying treatments with unprecedented efficacy in the fields of endocrinology (weight loss and type 2 diabetes), immunology, neurology, and musculoskeletal diseases.